Drug design, development and therapy
Tegileridine versus Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Delivery: A Randomized Double-Blind Trial
By Hu J, Ou L, Wei F and 5 others.
Abstract
Background
Postoperative nausea and vomiting (PONV) remains one of the most common opioid-related adverse events after cesarean delivery despite multimodal analgesia. Tegileridine, a biased μ-opioid receptor agonist, may offer effective analgesia with fewer opioid-related adverse events. This randomized, double-blind trial compared tegileridine versus sufentanil for patient-controlled intravenous analgesia (PCIA) after cesarean delivery.
Methods
Chinese Clinical Trial Registry number: ChiCTR2600123056. Ninety-four parturients scheduled for elective cesarean were randomized to receive PCIA with tegileridine 5 mg or sufentanil 100 μg. The primary outcome was the 48-hour incidence of PONV. Secondary outcomes included other opioid-related adverse events (ORAEs), pain scores, PCIA bolus counts, rescue analgesia, Quality of Recovery 15 (QoR-15) scores, ambulation time, and hospital stay.